Key takeaways
- We found six published studies that gave BPC-157 to people, 118 participants in all, most without a control group (PubMed and FDA’s 2026 review, 21 Nov 2026).
- By our count from the sources, 15 participants were women and 33 men, 32 of them volunteers whose 2003 abstract title calls them male; the sources do not give the sex of 70.
- The one study that enrolled only women had 12 participants aged 39 to 76 and no control group.
- All four records on ClinicalTrials.gov accept both sexes, set a minimum age of 18 and exclude pregnancy and breastfeeding; one also excludes people in a formal anti-doping testing programme unless the relevant authority approves.
- Of 109 PubMed records of BPC-157 animal studies, 83 carry only the male tag and 12 only the female tag (our count, 21 Nov 2026).
01Who was in the BPC-157 studies, at a glance
If you searched “bpc-157 for women”, the question the studies can answer is narrower: whom they enrolled, by sex and age, and whom they left out. This page describes study design. It gives no advice about any person.
Healthy volunteers
Two studies enrolled people the authors describe as healthy: 32 in conference abstracts from 2002 and 2003, and 2 in a 2025 pilot.
Patients
Four studies enrolled patients: 53, 16, 12 and 3. The 12 were all women; the 3 received BPC-157 with other agents.
Rats and mice
Of 109 PubMed records of BPC-157 animal studies, 83 carry only the male tag, as PubMed indexes them (our count).
Six studies, 118 people, most of them without a control group: every published study we found that gave BPC-157 to people (PubMed and FDA’s 2026 review, 21 November 2026). Reports made to FDA are a separate record; they show no cause and no rate. Why the grade stays Preclinical, and where BPC-157 stands with regulators: the BPC-157 guide.
02Who was in each published BPC-157 study?
Every published study we found that gave BPC-157 to people, with what its source says about sex and age.
| Study | Design | People | Sex | Age |
|---|---|---|---|---|
| Veljaca et al., 2002 and 2003 | Randomised, placebo-controlled; conference abstracts, summarised by FDA staff | 32 healthy volunteers, 24 given BPC-157 | Male, in the title of the 2003 abstract | Not given in FDA’s summary |
| Ruenzi et al., 2005 | Randomised, placebo-controlled; conference abstract, summarised by FDA staff | 53 patients; 46 completed | Not given | Not given |
| Lee and Padgett, 2021 | Chart review with a phone survey; no control group | 17 patients identified, 16 reached | Not given in the abstract | Not given in the abstract |
| Lee, Walker and Ayadi, 2024 | Single group; no control group | 12 patients | All women | 39 to 76; mean 58.3 |
| Lee and Burgess, 2025 | Two-person pilot; no control group | 2 adults described as healthy, both given BPC-157 before the study | One man, one woman | 58 and 68 |
| Froum et al., 2026 | Case report; no control group | 3 patients given BPC-157 with TB-500 and other agents | Two women; one not stated | 38, 48 and 85 |
How we counted. Our calculation from the six sources: 15 women (12 + 1 + 2), 33 men (32 + 1) and 70 people whose sex the sources we read do not give (53 + 16 + 1). The 32 are counted as men because the title of the 2003 abstract, as FDA’s 2026 review lists it, describes “Healthy Male Volunteers”; we could not read the abstract itself. Ages are given for 17 of the 118.
The patient groups were defined by specific conditions, named on BPC-157 human studies with each study’s design. A 2026 systematic review of the three full papers, 30 people, rated the certainty of the evidence “very low”.
03Whom do the registered BPC-157 trials include and exclude?
ClinicalTrials.gov lists four records that give BPC-157 (21 November 2026). Each states who may take part. None has posted results, so none shows who actually took part.
| Record | Design and status | Sexes | Ages | Healthy volunteers | Exclusions, quoted from the record |
|---|---|---|---|---|---|
| NCT02637284 | Phase 1, randomised, placebo-controlled; 42 planned; status unknown, last updated Dec 2015 | “Both genders” | 18 to 35 | Yes | “Pregnant or lactating women” |
| NCT07752381 | Single group, no control; 40 enrolled; completed Nov 2025; no results posted | “male or female” | 18 to 65 | Yes | “Any women who are pregnant, breastfeeding, or trying to conceive” |
| NCT07437547 | Phase 2, randomised, placebo-controlled; 120 planned; recruiting | All | 18 to 45 | No | “Pregnant or breastfeeding”; people “Currently subject to a formal anti-doping testing program”, unless the relevant authority explicitly approves |
| NCT07803250 | Phase 1, randomised; 30 planned; not yet recruiting | “Males and Females, 18 years old or older” | 18, no upper limit | No | “Pregnant or breastfeeding status”; hormone or testosterone replacement therapy in the past 12 months |
Two records also ask for a negative pregnancy test from participants who could become pregnant. NCT07752381 was completed in November 2025, has posted no results, and we found no publication of it. The two records that take no healthy volunteers enrol patients with a recent muscle injury and patients scheduled for shoulder surgery. A registration is a plan, not a result.
04Were the animal studies in male or female animals?
Most BPC-157 research is in animals. PubMed’s indexers tag each animal study with the sex of the animals used, when the paper reports it.
| Sex tag on animal-study records naming BPC-157 | Records |
|---|---|
| Male only | 83 |
| Female only | 12 |
| Both | 6 |
| Neither tag | 8 |
| All animal-study records, humans excluded | 109 |
Our count from PubMed’s indexing tags (Animals, Male, Female, Humans), run on 21 November 2026 over 240 records that name BPC-157 or its other names in the title or abstract. Tags can be missing or wrong, so the count describes how the records are indexed, not a reading of every paper. One example: a 2026 tendon study used 32 male rats. FDA staff describe toxicity studies of BPC-157 in rats and dogs of both sexes.
A result in male rats does not show how female animals respond, and an animal result of either sex is not evidence of an effect in people.
05What the BPC-157 studies can’t tell you about sex, age or pregnancy
What the record does not cover, by design.
Whether anything differs by sex
We found no study of BPC-157 that compares women and men (PubMed search for sex-difference terms, 21 Nov 2026). The one all-women study had 12 participants and no control group.
Pregnancy and breastfeeding
We found no human study of BPC-157 in pregnancy (PubMed, 21 Nov 2026), and all four registered trials list pregnancy and breastfeeding among their exclusions.
Older and younger people
Ages are known for 17 participants, the oldest 85. The four registered trials set a minimum age of 18; three set an upper limit, from 35 to 65.
What a vial holds
Material sold online is not the product these studies tested. What a given vial holds is shown only by the identity result on that lot’s report.
How to find that line on a lab report: how to read a COA. Why no page on this site gives an amount for anyone: why we publish no doses.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.